Emil Pharmaceutical Industries Pvt Ltd

Emil Pharmaceutical Industries Pvt. Ltd., established in 1989, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH1986PTC039809. As of the latest available data, Emil Pharmaceutical Industries has an authorized capital of ₹1000.0 lakhs and a paid-up capital of ₹764.56 lakhs, reflecting a paid-up capital percentage of 76.45614%.

The company operates in the manufacturing sector, specifically focusing on pharmaceuticals, medicinal chemicals, and botanical products. Emil Pharmaceutical Industries has a workforce of approximately 201 to 500 employees, indicating a substantial operational scale. Their product portfolio includes tablets, capsules, syrups, and injections, catering to various therapeutic categories. The company's official website is www.emilpharma.in, providing comprehensive information about their products and services.

Emil Pharmaceutical Industries Pvt. Ltd. operates multiple manufacturing units, including a new greenfield facility, to enhance its production capabilities. The company has two existing units with a combined volume of approximately 3.3 billion tablets, 1.8 billion capsules, and 42 million dry powder packs. Unit 1 is accredited with Good Manufacturing Practice (GMP) certification, while Unit 2 holds certifications from the World Health Organization (WHO) GMP, FDA Philippines, NMRA Sri Lanka, NAFDAC Nigeria, FDA Ghana, Ministry of Health (MOH) UAE, and PPB Kenya. The new greenfield manufacturing facility is expected to double the company's manufacturing capabilities by 2025.

The leadership team at Emil Pharmaceutical Industries Pvt. Ltd. comprises experienced professionals dedicated to steering the company towards growth and innovation. Key executives include:

• Tushar Anil Korday: Co-founder and Director, serving since May 13, 1986.
• Rajendra Fattesinh Gole: Co-founder and Technical Director, serving since May 13, 1986.
• Sumegha Sanjiv Patange: Director, serving since February 24, 2004.
• Manjiri Anil Devdhar: Director, serving since February 24, 2004.

These leaders bring a wealth of experience and strategic vision to the company, contributing to its sustained success in the pharmaceutical industry.

Emil Pharmaceutical Industries Pvt. Ltd. has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has made substantial progress in obtaining regulatory approvals and market access in these regions. For instance, Emil has been advancing towards EU Good Manufacturing Practice (GMP) and US FDA approvals to expand its market reach and product portfolio.

In the United States, the company has been actively pursuing facility registrations and approvals for its Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs). While specific details regarding FDA facility registrations and inspection history are not publicly disclosed, Emil's commitment to meeting international standards suggests a proactive approach to compliance.

In the European Union, Emil Pharmaceutical Industries has been working towards obtaining EU GMP certifications, which are essential for market access. The company's efforts to modernize existing units and build new manufacturing facilities indicate a strategic focus on meeting the stringent requirements of the EU market.

Emil Pharmaceutical Industries Pvt. Ltd. has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are registered in over 25 countries, including regions such as Central and South America, Africa, and Southeast Asia. This extensive registration underscores Emil's commitment to expanding its global footprint and providing affordable healthcare solutions worldwide.

The company's engagement with the World Health Organization (WHO) for prequalification and other international certifications has facilitated access to these emerging markets. By obtaining certifications from regulatory bodies such as NAFDAC Nigeria, FDA Ghana, and others, Emil Pharmaceutical Industries has enhanced its credibility and marketability in these regions. (pharmasource.global)

Emil Pharmaceutical Industries Pvt. Ltd. has adopted a strategic approach to geographic diversification, aiming to mitigate concentration risks and capitalize on growth opportunities in various regions. The company's export data indicates a focus on markets in Central and South America, Africa, and Southeast Asia. By registering products in over 25 countries, Emil has effectively diversified its market presence, reducing dependency on any single region.

The strategic direction includes strengthening brands in international markets, as evidenced by Emil's strong presence in the Chilean market, where it ranked among the top five Indian exporters to Chile in 2021. This geographic diversification strategy positions Emil Pharmaceutical Industries to leverage growth opportunities across different regions while managing risks associated with market fluctuations.

Emil Pharmaceutical Industries Pvt. Ltd. has been actively pursuing compliance with the U.S. Food and Drug Administration (FDA) regulations to enhance its market presence in the United States. The company has been advancing towards obtaining FDA approvals for its manufacturing facilities and products. While specific details regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly disclosed, Emil's commitment to meeting international standards suggests a proactive approach to compliance.

Emil Pharmaceutical Industries Pvt. Ltd. has been working towards obtaining EU GMP certifications, which are essential for market access in the European Union. The company's efforts to modernize existing units and build new manufacturing facilities indicate a strategic focus on meeting the stringent requirements of the EU market.

Emil Pharmaceutical Industries Pvt. Ltd. operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses from CDSCO, ensuring compliance with national standards for pharmaceutical manufacturing. Additionally, Emil has obtained approvals from various state drug controllers and export No Objection Certificates (NOCs), facilitating its export operations. The company's commitment to adhering to Indian regulatory requirements underscores its dedication to quality and compliance.

As of the latest available information, there are no publicly disclosed records of Form 483 observations, warning letters, or import alerts issued to Emil Pharmaceutical Industries Pvt. Ltd. The company's proactive approach to regulatory compliance and its efforts to obtain certifications from various international regulatory bodies suggest a commitment to maintaining high standards of quality and safety.

Emil Pharmaceutical Industries Pvt. Ltd. operates in a competitive landscape, facing competition from both domestic and international pharmaceutical manufacturers. Key competitors include established Indian pharmaceutical companies and multinational corporations with a presence in the same therapeutic categories. Emil's focus on quality, affordability, and regulatory compliance positions it favorably in the market. The company's strategic partnerships with multinational firms such as Pfizer, Merck, and GSK further enhance its competitive standing.

Emil Pharmaceutical Industries Pvt. Ltd. differentiates itself through several key strengths:

• Patient-Centric Approach: Emil prioritizes the well-being of patients, ensuring that its products meet high-quality standards and are accessible.
• Cost Competitiveness: The company offers affordable healthcare solutions without compromising on quality.
• Timely Deliveries: Emil emphasizes efficient supply chain management to ensure prompt delivery of products.
• Broad Portfolio: With over 250 formulations across 20 therapeutic categories, Emil offers a diverse product range.
• In-House Capabilities: The company has in-house formulation and development, as well as quality testing facilities.

These differentiators contribute to Emil's strong reputation in the pharmaceutical industry.

Emil Pharmaceutical Industries Pvt. Ltd. is strategically positioned as a Contract Development and Manufacturing Organization (CDMO), focusing on the production of generic pharmaceutical formulations. The company's future outlook includes expanding its product portfolio and market reach by obtaining EU